Ai Yanai1,2, Ryuichi Harada3, Ren Iwata4, Takeo Yoshikawa2, Yoichi Ishikawa4, Shozo Furumoto4, Takanori Ishida1, Kazuhiko Yanai2,4. 1. Department of Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. 2. Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan. 3. Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan. dragon1@med.tohoku.ac.jp. 4. Cyclotron and Radioisotope Center (CYRIC), Tohoku University, Sendai, Japan.
Abstract
PURPOSE: Although a preparation method for F-18-labeled proteins that used a cell-free translation system and 4-[18F]fluoro-L-proline instead of L-proline has been reported, its introduction depends on amino acid sequences of target proteins. The purpose of the study was to propose site-specific labeling method of F-18 by using cell-free translation systems supplemented with an engineered orthogonal aminoacyl-tRNA synthetase derived from Methanocaldococcus jannaschii (pCNF-RS)/suppressor tRNA (tRNACUAopt) pair, O-2-[18F]fluoroethyl-L-tyrosine ([18F]FET), and template DNA inserted with an amber codon. PROCEDURES: [18F]FET was prepared from the corresponding precursor and determined whether [18F]FET could be incorporated into an affibody molecule for human epidermal growth factor receptor type 2 (HER2; ZHER2:342) as the 21st amino acid used with the pCNF-RS-tRNACUAopt pair and template DNA inserted with an amber codon in a cell-free translation system. Using SKOV-3 cells, we performed an in vitro binding assay of [18F]FET-ZHER2:342. Furthermore, in vivo positron emission tomography (PET) imaging in SKOV-3 xenograft-bearing mice was performed after the intravenous administration of [18F]FET-ZHER2:342. RESULTS: [18F]FET was successfully incorporated into proteins by using commercially available cell-free protein synthesis reagents with a pCNF-RS-tRNACUAopt pair and template DNA of the desired proteins inserted with an amber codon. The mean radiochemical yield (non-decay-corrected) of [18F]FET-ZHER2:342 was 6.5 ± 4.1 %. An in vitro cell binding assay revealed that SKOV-3 cells-bound [18F]FET-ZHER2:342 expressed HER2. The in vivo PET imaging in SKOV-3 xenograft-bearing mice revealed that [18F]FET-ZHER2:342 accumulated in SKOV-3 xenografts. CONCLUSION: The method proposed in this study might be useful for preparing proteins with F-18 and molecular imaging in the preclinical development.
PURPOSE: Although a preparation method for F-18-labeled proteins that used a cell-free translation system and 4-[18F]fluoro-L-proline instead of L-proline has been reported, its introduction depends on amino acid sequences of target proteins. The purpose of the study was to propose site-specific labeling method of F-18 by using cell-free translation systems supplemented with an engineered orthogonal aminoacyl-tRNA synthetase derived from Methanocaldococcus jannaschii (pCNF-RS)/suppressor tRNA (tRNACUAopt) pair, O-2-[18F]fluoroethyl-L-tyrosine ([18F]FET), and template DNA inserted with an amber codon. PROCEDURES: [18F]FET was prepared from the corresponding precursor and determined whether [18F]FET could be incorporated into an affibody molecule for human epidermal growth factor receptor type 2 (HER2; ZHER2:342) as the 21st amino acid used with the pCNF-RS-tRNACUAopt pair and template DNA inserted with an amber codon in a cell-free translation system. Using SKOV-3 cells, we performed an in vitro binding assay of [18F]FET-ZHER2:342. Furthermore, in vivo positron emission tomography (PET) imaging in SKOV-3 xenograft-bearing mice was performed after the intravenous administration of [18F]FET-ZHER2:342. RESULTS: [18F]FET was successfully incorporated into proteins by using commercially available cell-free protein synthesis reagents with a pCNF-RS-tRNACUAopt pair and template DNA of the desired proteins inserted with an amber codon. The mean radiochemical yield (non-decay-corrected) of [18F]FET-ZHER2:342 was 6.5 ± 4.1 %. An in vitro cell binding assay revealed that SKOV-3 cells-bound [18F]FET-ZHER2:342 expressed HER2. The in vivo PET imaging in SKOV-3 xenograft-bearing mice revealed that [18F]FET-ZHER2:342 accumulated in SKOV-3 xenografts. CONCLUSION: The method proposed in this study might be useful for preparing proteins with F-18 and molecular imaging in the preclinical development.
Entities:
Keywords:
Affibody; Cell-free protein synthesis; Engineered orthogonal aminoacyl-tRNA synthetase; [18F]FET
Authors: Anna Orlova; Vladimir Tolmachev; Rikard Pehrson; Malin Lindborg; Thuy Tran; Mattias Sandström; Fredrik Y Nilsson; Anders Wennborg; Lars Abrahmsén; Joachim Feldwisch Journal: Cancer Res Date: 2007-03-01 Impact factor: 12.701
Authors: Marion Rapp; Alexander Heinzel; Norbert Galldiks; Gabriele Stoffels; Jörg Felsberg; Christian Ewelt; Michael Sabel; Hans J Steiger; Guido Reifenberger; Thomas Beez; Heinz H Coenen; Frank W Floeth; Karl-Josef Langen Journal: J Nucl Med Date: 2012-12-11 Impact factor: 10.057
Authors: Sara Ahlgren; Anna Orlova; Helena Wållberg; Monika Hansson; Mattias Sandström; Richard Lewsley; Anders Wennborg; Lars Abrahmsén; Vladimir Tolmachev; Joachim Feldwisch Journal: J Nucl Med Date: 2010-06-16 Impact factor: 10.057
Authors: Charles Eigenbrot; Mark Ultsch; Anatoly Dubnovitsky; Lars Abrahmsén; Torleif Härd Journal: Proc Natl Acad Sci U S A Date: 2010-08-09 Impact factor: 11.205
Authors: James T Koerber; Nathan D Thomsen; Brett T Hannigan; William F Degrado; James A Wells Journal: Nat Biotechnol Date: 2013-08-18 Impact factor: 54.908
Authors: Ksenia Lisova; Bao Ying Chen; Jia Wang; Kelly Mun-Ming Fong; Peter M Clark; R Michael van Dam Journal: EJNMMI Radiopharm Chem Date: 2019-12-31